Novo Nordisk ends Wegovy deal with Hims & Hers
The “Wegovy” brand slimming syringe is sold at the Achat Pharmacy in Mitte. The “Wegovy” slimming syringe has been in Germany for a year.
Jens Kalane | Picture Alliance | Getty Images
Novo Nordisk On Monday, he said he ended his cooperation. HIMS & HERS Because of concerns about the encouragement of Telealth Company’s sales and weight loss medicine Wegovy’s cheaper knochasts.
The shares of Hold & Hers were more than 34% lower on Monday and Novo Nordisk’s shares closed more than 5% lower.
In April, Novo Nordisk said that in April, wegovy will offer Wegovy through various Telehealth companies such as HIMS & HIMSI to expand access to the injection of box office records.
The end of the scarcity of Wegovy meant that merger pharmacies were legally limited to making and selling cheaper, unapproved versions of the drug until 22 May. Telehealth said that patients may still need personalized compound versions of Wegovy when patients are medically necessary.
On Monday, however, Novo Nordisk said that HIMS & HERS did not comply with the law that prohibits the mass sales of compound drugs under the “false guise of personalization”. The drug producer also accused the “deceptive” marketing that risks patient safety.
“We waited for their efforts to unite personalization over time. When we didn’t see this, we had to make a choice on behalf of the patients, D Dave Moore,” we had to make a choice. ” He said. He continued: “We have been a solid thing that patient safety is our primary focal point.”
“Our expectation was that [Hims & Hers’] Business focus was to transfer to real, safe, approved drugs, Moore said Moore, Novo Nordisk, the drug producer directly through a third party that manages the online pharmacy for the consumer, he said he would not get any fees of termination of cooperation.
One expression Andrew Dudum, HIMS & HERS CEO in X, said that the company “Novo Nordisk administration was disappointed to see the public misleading the public”.
In recent weeks, DUDUM said that Novo Nordisk’s commercial team is increasingly pressing to control clinical standards and to direct patients to Wegovy, regardless of whether they are the best clinically for patients. ” HIMS & HERS plays a role in maintaining the ability of providers and patients to control individual treatment decisions and added, “It will not endanger the integrity of our platform to appease or maintain a cooperation.”
He said that HIMS & HERS will continue to offer various treatment, including Wegovy to allow providers to meet their individual needs.
In a note on Monday, Citi Analyst Daniel Grosslight said that the termination of cooperation increases themselves & his’ legal risk “significantly”. The authority added that when it was initially announced, Telehealth did not contain any efforts to prevent compound efforts.
During Famine for food and pharmaceutical administrationPharmacists legally can make compound versions of brand drugs. They can also be produced according to the situation when they are not medically required for a patient, as well as allergic to a particular component in a branded drug that they cannot swallow a pill or in a branded drug.
However, drug producers and some health professionals pushed them back to the application because they did not approve of FDA compound drugs.
Novo Nordisk said the branded version of Wegovy will continue to present the branded version of Wegovy that “shares our commitment to safe and effective medical treatment for patients with chronic diseases”.
Moore said Novo Nordisk’s pharmacies reduce or stop quitting a few other mass unification pharmacies. The authority added that the company will “enter the legal front” to reduce the illegal compound and with the FDA.
In a statement on Monday, Novo Nordisk said that he carried out an investigation that identified that the united pharmacies used in Wegovy knockouts sold by Telehealth companies were produced by foreign suppliers in China. Drug producer A report was given In April, a large share of these Chinese suppliers from the Brookings institution was never controlled by the FDA, and many of the audited had drug quality assurance violations.
“These drugs from sources around the world are not approved even in the countries where they emerge, and this is a problem.” He said.
